We are live on ! Find out more

Eloxx Pharmaceuticals

ELOX

Market cap $51.3M

12.71 USD

-0.21

1.63%

At close Updated Nov 4, 11:57 AM EST

1 day

-1.63%

5 days

-7.76%

1 month

-17.52%

3 months

-31.04%

6 months

15.44%

Year to date

15.44%

1 year

15.44%

5 years

15.44%

10 years

15.44%

About: Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Employees: 7

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 85.7%

Negative 0%

Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference

ARLINGTON, Mass., Nov. 2, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that Sumit Aggarwal, President and Chief Executive Officer, will present at the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9–11, 2026.

Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKD EXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo for 52 weeks, with annualized htTKV growth as the primary endpoint; first patient dosing expected in 3Q 2027 and topline data in 1H 2029 FDA pre-IND feedback indicated that a substantial and durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV as a potential surrogate endpoint for accelerated approval in ADPKD ARLINGTON, Mass., Oct. 29, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for exaluren for the treatment of nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD).

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D.

EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to ex aluren or placebo, with annualized htTKV growth as the primary endpoint Substantial, durable htTKV effect could support Breakthrough Therapy Designation; FDA also lists htTKV as a potential surrogate endpoint for accelerated approval in ADPKD First patient dosing expected in 3Q 2027, and 52-week topline data expected in 1H 2029 Orphan drug designation granted for ADPKD in the US in addition to Europe T.R. Srinivas, M.D.

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D.

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board experience, including current service as Chairman of Entera Bio and as a director of Precision BioSciences ARLINGTON, Mass., Oct. 19, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the appointment of Geno Germano to its Board of Directors, effective October 19, 2026.

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass., Sept. 11, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS).

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 European Commission granted orphan designation for exaluren in ADPKD Cash and cash equivalents of $62.0 million as of June 30, 2026, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) ARLINGTON, Mass., Aug. 12, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

See News Rankings

Price charts implemented using Lightweight Charts™